Kawasaki disease: Part II. Complications and treatment

Stephanie Bayers, Stanford T. Shulman, Amy S. Paller*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

40 Scopus citations


Kawasaki disease, or mucocutaneous lymph node syndrome, is the leading cause of acquired heart disease in children in the United States and other developed countries. Coronary artery lesions are the most significant cause of morbidity and mortality. Treatment should ideally be provided within 10 days of symptom onset to reduce the risk of coronary artery complications. The standard of care for treatment is intravenous immunoglobulin plus aspirin, but adding corticosteroids may provide additional benefit for high-risk patients. Some patients do not respond to intravenous immunoglobulin and require additional therapy. Part II of this continuing medical education article will focus on the complications of Kawasaki disease and potential treatment options.

Original languageEnglish (US)
Pages (from-to)513.e1-513.e8
JournalJournal of the American Academy of Dermatology
Issue number4
StatePublished - Oct 2013


  • aspirin
  • complications
  • coronary artery lesions
  • corticosteroids
  • immunoglobulin Kawasaki disease
  • intravenous
  • mucocutaneous lymph node syndrome
  • pediatric
  • treatment
  • vasculitis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Kawasaki disease: Part II. Complications and treatment'. Together they form a unique fingerprint.

Cite this